Affluent Medical's Transformative H1 2025 Efforts

In the first half of 2025, Affluent Medical made significant advancements in its medical portfolio. The completion of the pilot phase and initiation of the pivotal phase for the Artus urinary sphincter marked critical progress. This device is designed to aid over 400 million people globally suffering from urinary incontinence. Simultaneously, Affluent advanced its Kalios mitral ring for potential U.S. market access, backed by FDA support and a collaboration with Edwards Lifesciences.

The Epygon mitral valve programme also gained traction, expanding its clinical reach in Europe. The device, which mimics a natural mitral valve, is seen as pivotal for treating severe mitral valve insufficiency without risky surgeries.

Additionally, new strategic medical appointments were made, bolstering expertise as Affluent moves towards the marketing phase. Financially, the company secured €5.4 million through convertible bonds, extending cash reserves till end-2025, reflecting shareholder confidence.